Τρίτη 2 Μαΐου 2017

Phase I results of novel antibody drug conjugate against folate receptor a

Results from a phase 1 dose-escalation study evaluating mirvetuximab soravtansine (IMGN853) in patients with folate receptor alpha (FRα)-positive solid tumours were published in the journal Cancer. The previously disclosed data demonstrated encouraging...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pT7LgM
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις